Michael D. Casey
Plus aucun poste en cours
Historique de carrière de Michael D. Casey
Anciens postes connus de Michael D. Casey
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CELGENE | Directeur/Membre du Conseil | 01/08/2002 | 20/11/2019 |
| Independent Dir/Board Member | 01/06/2007 | 20/11/2019 | |
| ABAXIS INC | Directeur/Membre du Conseil | 12/10/2010 | 01/07/2018 |
| Independent Dir/Board Member | 12/10/2010 | 01/07/2018 | |
| DURECT CORPORATION | Directeur/Membre du Conseil | 01/03/2004 | 31/12/2013 |
| Independent Dir/Board Member | 15/11/2011 | 31/12/2013 | |
| SAREPTA THERAPEUTICS, INC. | Président | 01/05/2006 | 07/06/2010 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Directeur/Membre du Conseil | 01/06/2002 | 25/01/2010 |
| CAPSTONE HOLDING CORP. | Directeur/Membre du Conseil | 01/01/2004 | 10/05/2007 |
Cholestech Corp.
 Cholestech Corp. Medical SpecialtiesHealth Technology Cholestech Corp. provides diagnostic tools and information for risk assessment and therapeutic monitoring of heart disease, inflammatory disorders, and diabetes. It manufactures LDX System, multi-analytic testing system, and accessories to perform individual tests. The company was founded in 1988 and is headquartered in Hayward, CA. | Directeur/Membre du Conseil | 01/01/2007 | 01/01/2007 |
Bone Care International, Inc.
 Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI. | Directeur/Membre du Conseil | 01/01/2005 | 01/01/2005 |
SICOR, Inc.
 SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Directeur/Membre du Conseil | 01/01/2004 | 01/01/2004 |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░░░░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░ ░░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Statistiques
Internationale
| Etats-Unis | 15 |
Opérationnelle
| Director/Board Member | 8 |
| Independent Dir/Board Member | 3 |
| President | 3 |
Sectorielle
| Health Technology | 12 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CAPSTONE HOLDING CORP. | Health Technology |
| DURECT CORPORATION | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Matrix Pharmaceutical, Inc.
 Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | Health Technology |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
| McNeil Pharmaceutical | |
| Ortho Pharmaceutical Corp. | |
Abaxis, Inc.
 Abaxis, Inc. Medical SpecialtiesHealth Technology ABAXIS, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems. It operates through the following segments: Medical Market, Veterinary Market, and Other. The Medical Market segment serves a customer group consisting of physicians’ office practices across multiple specialties, urgent care, outpatient and walk-in clinics, health screening operations, home care providers, nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies, hospital laboratories, military installations, pharmaceutical clinical trials, and cruise ship lines. The Veterinary Market segment focuses on animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies, and private research laboratories. The company was founded by Vladimir E. Ostoich in April 1989 and is headquartered in Union City, CA. | Health Technology |
| Schein Pharmaceutical, Inc. | Health Technology |
Cholestech Corp.
Cholestech Corp. Medical SpecialtiesHealth Technology Cholestech Corp. provides diagnostic tools and information for risk assessment and therapeutic monitoring of heart disease, inflammatory disorders, and diabetes. It manufactures LDX System, multi-analytic testing system, and accessories to perform individual tests. The company was founded in 1988 and is headquartered in Hayward, CA. | Health Technology |
Bone Care International, Inc.
Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI. | Health Technology |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Health Technology |
- Bourse
- Insiders
- Michael D. Casey
- Expérience
